China in Focus

From cross-border deals to start-ups, faster clinical data is fueling the China innovation story, turning biopharmas from Shanghai to Beijing into global players. MNCs and Western VCs have been the first to capitalize, sourcing innovation from China at record levels. Now, Western biotechs are embracing the search for deals in Asia. Testing faster in humans is also a recipe for Western and Asia biotechs to de-risk their own compounds, working with China partners. This collection showcases BioCentury's longstanding expertise on the China biotech ecosystem.

Sign up now (free) to access the featured stories below and put BioCentury to work for you.